Literature DB >> 22457292

The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.

Peter Vickerman1, Jason Grebely, Gregory J Dore, Rachel Sacks-Davis, Kimberly Page, David L Thomas, William O Osburn, Andrea L Cox, Campbell K Aitken, Matthew Hickman, Margaret Hellard.   

Abstract

INTRODUCTION: Studies have explored whether spontaneous clearance of hepatitis C virus (HCV) infection decreases the likelihood of reinfection or increases the probability of clearance. This analysis investigates whether the conflicting findings from these studies could be due to differences in frequency of HCV RNA testing.
METHODS: A model simulated the dynamics of HCV reinfection and clearance among a cohort of injection drug users. For different reinfection incidence and clearance rates, the model evaluated the accuracy of epidemiological studies that used different HCV testing frequencies.
RESULTS: Experimental estimates for the reinfection incidence and clearance probability will be accurate (<20% error) if the testing interval is less than the reinfection clearance duration. Otherwise, experimental estimates can greatly underestimate the real values (≤66% error if reinfection duration is 1 month and the testing interval is 3 months). Uncertainty in experimental estimates also increases at lower reinfection incidences, whereas for lower clearance probabilities the uncertainty in the estimated clearance probability increases but estimated reinfection incidence decreases. DISCUSSION: Differences in HCV testing interval could account for most between-study variability in the estimated probability of clearing reinfections and is likely to have biased reinfection incidence estimates. Our findings suggest that a high reinfection clearance probability (>75%) is consistent with data.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22457292      PMCID: PMC3324399          DOI: 10.1093/infdis/jis213

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Low incidence of HCV reinfection: exposure, testing frequency, or protective immunity?

Authors:  Gregory J Dore; Joanne Micallef
Journal:  Hepatology       Date:  2007-05       Impact factor: 17.425

2.  HCV reinfection studies and the door to vaccine development.

Authors:  Jason Grebely; David L Thomas; Gregory J Dore
Journal:  J Hepatol       Date:  2009-07-17       Impact factor: 25.083

3.  Hepatitis C virus reinfection in injection drug users.

Authors:  Jason Grebely; Brian Conway; Jesse D Raffa; Calvin Lai; Mel Krajden; Mark W Tyndall
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

4.  Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees.

Authors:  Michelina Nascimbeni; Eishiro Mizukoshi; Markus Bosmann; Marian E Major; Kathleen Mihalik; Charles M Rice; Stephen M Feinstone; Barbara Rehermann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?

Authors:  H E Harris; K P Eldridge; S Harbour; G Alexander; C-G Teo; M E Ramsay
Journal:  J Viral Hepat       Date:  2007-03       Impact factor: 3.728

6.  Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.

Authors:  William O Osburn; Brian E Fisher; Kimberly A Dowd; Giselle Urban; Lin Liu; Stuart C Ray; David L Thomas; Andrea L Cox
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

7.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

Authors:  J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

8.  High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.

Authors:  Campbell Kynoch Aitken; Jennifer Lewis; Samantha Lilly Tracy; Timothy Spelman; David Scott Bowden; Mandvi Bharadwaj; Heidi Drummer; Margaret Hellard
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

9.  Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.

Authors:  S C Hadler; D P Francis; J E Maynard; S E Thompson; F N Judson; D F Echenberg; D G Ostrow; P M O'Malley; K A Penley; N L Altman
Journal:  N Engl J Med       Date:  1986-07-24       Impact factor: 91.245

10.  Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection.

Authors:  Naglaa H Shoukry; Arash Grakoui; Michael Houghton; David Y Chien; John Ghrayeb; Keith A Reimann; Christopher M Walker
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  20 in total

Review 1.  Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.

Authors:  A Esmaeili; A Mirzazadeh; G M Carter; A Esmaeili; B Hajarizadeh; H S Sacks; K A Page
Journal:  J Viral Hepat       Date:  2016-10-28       Impact factor: 3.728

2.  Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs.

Authors:  Andreea A Artenie; Nanor Minoyan; Brendan Jacka; Stine Høj; Didier Jutras-Aswad; Élise Roy; Lise Gauvin; Geng Zang; Julie Bruneau
Journal:  CMAJ       Date:  2019-04-29       Impact factor: 8.262

Review 3.  Hepatitis C virus vaccines among people who inject drugs.

Authors:  Andrea L Cox; David L Thomas
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

4.  Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons.

Authors:  Melanie R Walker; Hui Li; Suzy Teutsch; Brigid Betz-Stablein; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  J Clin Microbiol       Date:  2016-05-11       Impact factor: 5.948

Review 5.  Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine.

Authors:  Jason Grebely; Maria Prins; Margaret Hellard; Andrea L Cox; William O Osburn; Georg Lauer; Kimberly Page; Andrew R Lloyd; Gregory J Dore
Journal:  Lancet Infect Dis       Date:  2012-05       Impact factor: 25.071

6.  Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.

Authors:  Rachel Sacks-Davis; Jason Grebely; Gregory J Dore; William Osburn; Andrea L Cox; Thomas M Rice; Timothy Spelman; Julie Bruneau; Maria Prins; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Janke Schinkel; Todd M Allen; Meghan Morris; Behzad Hajarizadeh; Lisa Maher; Andrew R Lloyd; Kimberly Page; Margaret Hellard
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

7.  Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection.

Authors:  Kimberly Page; William Osburn; Jennifer Evans; Judith A Hahn; Paula Lum; Alice Asher; Eric Delwart; Leslie Tobler; Andrea L Cox; Michael P Busch
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

8.  Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.

Authors:  Jason Grebely; Meghan D Morris; Thomas M Rice; Julie Bruneau; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Georg Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Maria Prins; Gregory J Dore; Kimberly Page
Journal:  Int J Epidemiol       Date:  2012-11-30       Impact factor: 7.196

Review 9.  Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.

Authors:  Nick Scott; Margaret Hellard; Emma Sue McBryde
Journal:  Virulence       Date:  2015-08-25       Impact factor: 5.882

10.  Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study.

Authors:  Alain H Litwin; John Jost; Katherine Wagner; Moonseong Heo; Alison Karasz; Judith Feinberg; Arthur Y Kim; Paula J Lum; Shruti H Mehta; Lynn E Taylor; Judith I Tsui; Irene Pericot-Valverde; Kimberly Page
Journal:  Contemp Clin Trials       Date:  2019-10-24       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.